Developing a new method for targeted drug delivery using antibody complexes
Official title: Evaluation of Non-covalent Antibody Drug Complexes (ADCx) for Targeted Drug Delivery
Funded at University of Michigan at Ann Arbor · NIH-11015192 · Data updated 2026-11-12
This study is testing a new way to deliver cancer and autoimmune treatments that could make them safer and more effective by using special antibody-drug combinations to target the right cells, and it aims to help patients get better results without the usual side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | December 15, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $390,000 |
| NIH project number | 1R35GM156770-01 |
| Project ID | NIH-11015192 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with cancers or autoimmune conditions that are currently treated with antibody-drug conjugates.
✕Less likely to help
Patients who do not have cancer or autoimmune conditions may not benefit from this research.
What this research studies
This research focuses on creating a novel drug delivery system that utilizes non-covalent antibody-drug complexes (ADCx) to target specific cells more effectively. By binding an anti-drug antibody to a drug outside the body and using a secondary ligand to direct it to the desired cell type, this approach aims to improve the safety and efficacy of treatments, particularly for cancers and autoimmune conditions. The study seeks to eliminate the need for traditional linker payloads, which often lead to adverse effects and treatment failures. Patients may benefit from a more effective and safer treatment option if the ADCx method proves successful.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer and autoimmune disease treatments with fewer side effects.
How similar studies have gone: While antibody-drug conjugates have been widely studied, this non-covalent approach is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Bordeau, Brandon — University of Michigan at Ann Arbor
- Study coordinator: Bordeau, Brandon
Related research
Other NIH-funded projects on the same topics.
-
Expanding genetic testing for cancer risk in patients and families
This study is working to make it easier for cancer patients in Michigan to get genetic testing for cancer risk by improving how doctors gather family history and assess genetic risks, so that more people can receive the important evaluations they need.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Why the retina can sometimes heal itself and how we might help it heal
This NIH grant explores how inflammation and neural cells interact in the zebrafish retina to understand retinal neuron death and regeneration, with potential implications for human vision.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Understanding how work exposures and genes influence ALS risk
A study is building a long-term group of people at higher risk for ALS to see how their jobs, exposures at work, and genes together affect if and when the disease might develop.
-
An integrated mobile health program to reduce SAVA and mental health problems among female sex workers in Kenya
A new mobile health program aims to help female sex workers in Kenya avoid substance abuse, violence, HIV, and depression by delivering group therapy, online resources, and a peer discussion space.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.